Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Withdraws NDA for Controlled-Release Formulation of Tacrolimus in US
February 16, 2009
- FDA Advisory Committee Recommends Approval of Prasugrel
February 16, 2009
- Ministerial Ordinance Issued Prohibiting Online Sale of Class 1, 2 OTC Drugs
February 16, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 16, 2009
- Low Recognition Rate for AMD: Novartis Survey
February 16, 2009
- Lack of Information Prevents Use of More Generics
February 9, 2009
- Japan's First Oral Carbapenem Recommended for Approval
February 9, 2009
- REGULATORY NEWS IN BRIEF
February 9, 2009
- Insurance Products to Compensate Subjects in Interventional Studies under Development
February 9, 2009
- R&D NEWS IN BRIEF
February 9, 2009
- Taisho Toyama Aims at Becoming Market Leader for Anti-infection Drugs
February 9, 2009
- Selection of Medical Materials Important for DPC Hospitals: Dr Muto
February 9, 2009
- New Pfizer to Become World's Premier Biopharma Company: CEO Jeff Kindler
February 9, 2009
- PICCs Cut Treatment Costs by Reducing Incidence of Complications
February 9, 2009
- Acquisition of Wyeth Does Not Solve Problems: Datamonitor Report
February 9, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 9, 2009
- Astellas Interested in CV Therapeutics' Product Lineup
February 9, 2009
- Mochida to Develop OTC Versions of Epadel
February 9, 2009
- aRigen Licenses New Anti-Peptic Ulcer Agent to Taiho
February 9, 2009
- LDP Diet Members to Discuss Online Sale of OTC Drugs
February 9, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…